Market Cap | 10.99M | P/E | - | EPS this Y | 93.20% | Ern Qtrly Grth | - |
Income | -14.46M | Forward P/E | -0.35 | EPS next Y | - | 50D Avg Chg | -32.00% |
Sales | 129.18k | PEG | - | EPS past 5Y | - | 200D Avg Chg | -58.00% |
Dividend | N/A | Price/Book | 1.26 | EPS next 5Y | - | 52W High Chg | -92.00% |
Recommedations | 1.50 | Quick Ratio | 1.21 | Shares Outstanding | 3.07M | 52W Low Chg | 57.00% |
Insider Own | 11.74% | ROA | -175.81% | Shares Float | 2.71M | Beta | 1.11 |
Inst Own | 3.53% | ROE | - | Shares Shorted/Prior | 557.46K/232.05K | Price | 0.33 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 3,966,956 | Target Price | 23.00 |
Oper. Margin | -6,866.05% | Earnings Date | May 8 | Volume | 322,774 | Change | 1.26% |
Sonnet BioTherapeutics Holdings, Inc., a biotechnology company, owns a platform for biologic medicines of single or bifunctional action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead product candidate is SON-1010, a fully human single-chain version of interleukin 12 that is in Phase 1b/2a clinical trial for the treatment of solid tumor indications, including ovarian cancer, non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6, which is in Phase 1b/I2a clinical trail to treat chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy; and SON-1210, a bispecific compound for solid tumor indications, including colorectal cancer. It has a license agreement with New Life Therapeutics Pte, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin-6. The company is headquartered in Princeton, New Jersey.
Chardan Capital | Buy | Feb 15, 24 |
Ladenburg Thalmann | Buy | Nov 27, 23 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Dyrness Albert D. | Director Director | May 30 | Buy | 0.468 | 23,255 | 10,883 | 28,962 | 05/31/23 |
Bhatt Nailesh | Director Director | May 17 | Buy | 0.232 | 25,000 | 5,800 | 30,733 | 05/18/23 |
Mohan Pankaj | Chairman, President.. Chairman, President and CEO | May 15 | Buy | 0.223 | 371,600 | 82,867 | 553,331 | 05/15/23 |